Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Wu, Newton
Bai-Lin Wu, Newton, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20090176226 | METHOD FOR DIAGNOSING AUTISM SPECTRUM DISORDER - The present invention provides methods of diagnosing and/or predicting autism spectrum disorder comprising determining the presence of microdeletions and microduplications on chromosomes 15 and 16. | 07-09-2009 |
| 20090203014 | METHOD FOR DIAGNOSING AUTISM SPECTRUM DISORDER - The present invention provides methods of diagnosing and/or predicting autism spectrum disorder comprising determining the presence of microdeletions and microduplications on chromosomes 15 and 16. | 08-13-2009 |
Changwang Wu, Newton, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20090299214 | METHOD AND APPARATUS FOR QUANTITATIVE NERVE LOCALIZATION - A method for localizing a needle to a nerve, the method comprising: | 12-03-2009 |
Charlie Wu, Newton, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20090253274 | DISPOSABLE NEEDLE ELECTRODE WITH IDENTIFICATION, AND ALTERABLE, CONNECTOR INTERFACE - An interconnect for connecting a needle electrode to a neurological testing device, the interconnect comprising: | 10-08-2009 |
Chen-Lee Wu, Newton, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20090030618 | SYSTEM, METHOD AND SOFTWARE ARRANGEMENT FOR ANALYZING AND CORRELATING MOLECULAR PROFILES ASSOCIATED WITH ANATOMICAL STRUCTURES - A system, method and software arrangement according to exemplary embodiments of the present invention are provided which can use molecular profiles obtained from unaltered human tissue specimens for clinical purposes including disease diagnoses and treatment evaluations. For example, spatial distributions of chemical species including metabolites within the tissue may be obtained using radiological techniques such as magnetic resonance spectroscopy imaging. Disease-specific profiles may be obtained by comparing the distributions of chemical species obtained in ex vivo tissues with pathological observations made on them using statistical analysis. The disease-specific profiles may then be correlated with in vivo or ex vivo molecular profiles to obtain spatial maps that can provide a more sensitive and accurate detection of diseased tissue. Thus, such exemplary systems, methods and software arrangements can include the ability to receive information relating to the distribution of at least three chemical species in the tissue of interest, compare this information statistically to a predetermined profile and, based on the statistical correlation between the information and the profile, determine certain characteristics of the tissue of interest such as, e.g., the presence or absence of diseased tissue. | 01-29-2009 |
Chin-Lee Wu, Newton, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20090176218 | Method for the Diagnosis and Prognosis of Cancer - Disclosed are methods for prognostic evaluation, and diagnosis of cancers. The methods of the present invention allow for the diagnosis and prognosis of cancers by analyzing the levels of expression of an enzyme that is involved in the biosynthetic pathway of spermine within tissue samples containing cancerous tissues. In particular, the amount of enzyme mRNA detected in tissue sample correlates with disease status such that enzyme levels can be used to predict the presence of, as well as the metastatic potential of cancer. Thus, measuring the level of spermine pathway enzymes in biological samples provides a quick, easy, and safe screen that can be used to both diagnose and prognose cancer in a patient thus leading to more effective treatments and cures. | 07-09-2009 |
| 20100047787 | PROSTATE CANCER SURVIVAL AND RECURRENCE - The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to prostate cancer. In particular, the disclosure is based on the identities of genes that are correlated with patient survival and prostate cancer recurrence. The gene expression profiles may be embodied in nucleic acid expression, protein expression, or other expression formats and used to predict the survival of subjects afflicted with prostate cancer and to predict prostate cancer recurrence. The profiles may also be used in the study and/or diagnosis of prostate cancer cells and tissue as well as for the study and/or determination of prognosis of a patient. When used for diagnosis or prognosis, the profiles may be used to determine the treatment of prostate cancer based upon probable life expectancy and cancer recurrence and/or metastasis. | 02-25-2010 |
Kaida Wu, Newton, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20090124662 | Migrastatin analogs in the treatment of cancer - In one aspect, the present invention provides a method for treating colon and/or ovarian cancer in a subject comprising administering to a subject in need thereof a compound of general formula (I): wherein R1-R6, R, -R, Q, Y1, Y2 and n are as defined herein, wherein the compound is present in an amount effective to inhibit colon and/or ovarian tumor metastasis. | 05-14-2009 |
Xinyuan Wu, Newton, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20080261968 | Heterobicyclic metalloprotease inhibitors - The present invention relates generally to azabicyclic containing pharmaceutical agents, and in particular, to azabicyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azabicyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, which exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors. | 10-23-2008 |
| 20090137547 | Heterobicyclic metalloprotease inhibitors - The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors. | 05-28-2009 |
| 20090312312 | Heterobicyclic Metalloprotease Inhibitors - The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors. | 12-17-2009 |